Axovant Sciences has spun out its small molecule team into a startup called Arvelle, which will develop an anti-epileptic drug after raising more than $100m in external funding.
Neurological disorder therapy developer Axovant Sciences has spun off small molecule drug developer Arvelle Therapeutics with more than $100m in funding, and is retaining a 5% stake in the Switzerland-based startup.
The round included investment firms Andera Partners and NovaQuest Capital Management as well as private equity firm LSP, growth equity firm BRV Capital Management and asset manager HIG BioHealth Partners.
Arvelle is developing a medicine called cenobamate to treat partial-onset epileptic seizures, after receiving the European licence rights for…
